Equities
Health CareMedical Equipment and Services
  • Price (SEK)76.28
  • Today's Change0.300 / 0.39%
  • Shares traded73.35k
  • 1 Year change-19.71%
  • Beta0.9303
Data delayed at least 15 minutes, as of Jan 27 2023 08:47 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Elekta publ AB is a Sweden-based human care company that develops and sells clinical solutions for the treatment of cancer and brain disorder. The Company offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer care. The Company has four product areas: Elekta Neuroscience, which develops solutions for the diagnosis and treatment of neurological diseases; Elekta Oncology, which creates clinical solutions for radiation therapy, such as linear accelerators, integrated imaging systems and clinical solutions for patient positioning and immobilization; Elekta Brachytherapy, which is engaged in the treatment of cancer through internal radiation, and Elekta Software, which develops software solutions for patient information, workflow management and treatment planning in oncology. The Company owns the service business of Asesores Electronicos Especializados SA de CV (AEESA).

  • Revenue in SEK (TTM)15.25bn
  • Net income in SEK826.00m
  • Incorporated1972
  • Employees4.66k
  • Location
    Elekta AB (publ)Kungstensgatan 18STOCKHOLM 11357SwedenSWE
  • Phone+46 85 872544646
  • Fax+46 858725500
  • Websitehttps://www.elekta.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CellaVision AB651.19m125.79m6.01bn234.0047.789.9236.379.235.275.2727.3025.400.81021.727.643,255,925.0015.6518.7218.5222.7269.2870.7019.3221.741.8514.750.155229.0419.9616.3740.0715.9529.895.92
Xvivo Perfusion AB369.64m29.88m6.19bn118.00207.494.4883.9016.751.011.0112.4846.740.26541.244.904,017,837.002.15-0.30342.27-0.325871.7573.368.08-1.184.82--0.004--43.6613.34118.6440.2735.61--
Synsam AB (publ)5.15bn324.00m6.46bn3.25k19.942.536.801.252.162.1634.3317.020.66592.3414.05--4.20--5.75--76.35--6.31--0.59712.160.621--22.67--126.15------
BICO Group AB2.08bn40.80m7.30bn1.27k178.390.923422.833.500.59230.592332.54114.410.23720.91263.762,342,135.000.4586--0.5044--81.72--1.93--1.55--0.2002--------------
Arjo AB (publ)9.98bn447.00m10.31bn6.69k24.711.456.761.031.641.6436.6427.990.64843.796.14--2.903.444.525.3342.2044.394.475.340.73697.510.45342.6410.025.35-39.7630.52--11.20
Biotage AB1.52bn239.00m10.68bn510.0044.816.6832.087.013.613.6123.0424.230.80022.307.023,066,399.0012.5514.8715.3317.8061.2961.3715.6817.181.7511.600.109744.4712.7913.0316.9217.183.334.40
Revenio Group Oyj1.03bn241.77m11.22bn191.0046.4111.6339.3010.850.81060.81063.473.230.76787.208.33502,597.8017.8716.3121.1719.9850.9651.8823.2722.281.78--0.205469.8429.0027.4429.6324.259.80-14.40
Ossur hf7.34bn484.30m21.99bn3.67k46.273.5321.492.990.74710.747111.469.780.56572.416.731,331,360.003.805.594.866.5062.1363.036.718.700.575511.480.424910.0714.166.65929.844.631.66--
Elekta AB (publ)15.25bn826.00m28.01bn4.66k35.163.1814.941.842.162.1639.9123.890.59723.402.843,209,640.003.254.845.998.8637.1241.035.448.880.75584.650.384755.055.706.33-7.9755.9812.7119.14
Ambu A/S6.68bn139.84m32.92bn4.41k263.715.8457.014.930.37160.371617.5316.770.68611.926.151,007,938.001.445.081.726.2757.4759.902.097.080.932--0.302234.0110.7413.54-62.35-20.9428.54--
GN Store Nord A/S26.34bn1.01bn37.87bn8.17k35.163.2611.421.445.225.22136.8056.290.71873.064.892,423,492.002.959.044.3812.2051.4258.314.1111.120.51925.590.691133.6317.2912.7740.2610.0914.206.15
Getinge AB27.78bn2.71bn59.73bn11.11k23.642.1013.192.159.949.94102.00111.800.58292.486.712,589,337.005.733.346.904.4548.6748.069.835.781.4330.710.15140.67-9.294.06-8.3133.59-10.3615.20
Demant A/S28.05bn3.98bn68.45bn18.13k17.205.80--2.4411.4910.3781.1234.060.73282.055.311,106,131.0010.429.0718.4914.7875.1675.2314.2211.960.587945.490.62120.0023.758.33140.5013.0711.99--
Data as of Jan 27 2023. Currency figures normalised to Elekta AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

40.01%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 31 Jan 202233.68m9.14%
Nordea Investment Management ABas of 30 Nov 202219.08m5.18%
SEB Investment Management ABas of 31 Jan 202215.52m4.21%
Schroder Investment Management Ltd.as of 31 Jan 202213.67m3.71%
AMF Fonder ABas of 31 Oct 202112.83m3.48%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 202212.29m3.33%
Lannebo Fonder ABas of 31 Jan 202210.74m2.92%
Swedbank Robur Fonder ABas of 31 Jan 202210.45m2.84%
The Vanguard Group, Inc.as of 05 Jan 202310.05m2.73%
Didner & Gerge Fonder ABas of 31 Dec 20219.15m2.48%
More ▼
Data from 31 Dec 2021 - 30 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.